Back to Search
Start Over
[Hereditary ovarian carcinomas: clinico-biological features and treatment].
- Source :
-
Bulletin du cancer [Bull Cancer] 2014 Feb; Vol. 101 (2), pp. 167-74. - Publication Year :
- 2014
-
Abstract
- Hereditary ovarian cancers account for 10% of all cases. Two major syndromes with dominant autosomal transmission are identified. The most common one is breast-ovarian cancer syndrome due to BRCA1 and BRCA2 genes mutations, and the Lynch syndrome with mutated MMR genes is the other. Alterations in homologous recombination specifically observed in ovarian cancer with BRCA defects associated to Parp inhibition create a synthetic lethality of special interest. Numerous studies are in progress to explore this promising new approach. Furthermore, it seems that carcinogenesis of these two syndromes are different, suggesting alternative therapeutic options in the near future in order to improve prognosis of ovarian carcinomas.
- Subjects :
- Antineoplastic Agents adverse effects
BRCA2 Protein genetics
Female
Genes, BRCA1
Genes, BRCA2
Humans
Middle Aged
Mutation
Ovarian Neoplasms pathology
Phthalazines adverse effects
Piperazines adverse effects
Antineoplastic Agents therapeutic use
Ovarian Neoplasms drug therapy
Ovarian Neoplasms genetics
Phthalazines therapeutic use
Piperazines therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors
Subjects
Details
- Language :
- French
- ISSN :
- 1769-6917
- Volume :
- 101
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Bulletin du cancer
- Publication Type :
- Academic Journal
- Accession number :
- 24555961
- Full Text :
- https://doi.org/10.1684/bdc.2014.1888